Please Wait

Applying Filters...

Technical details about Spicamycin Analog, learn more about the structure, uses, toxicity, action, side effects and more

Spicamycin Analog

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

1 Suppliers, 1 USDMF

Spicamycin Analog
Chemistry
Full Screen View

1. Also known as: Spicamycin analog, Nsc650426, 151276-95-8, Krn5500, (2e,4e)-n-[2-[[(2r,3r,4r,5r,6s)-2-[(1s)-1,2-dihydroxyethyl]-4,5-dihydroxy-6-(7h-purin-6-ylamino)oxan-3-yl]amino]-2-oxoethyl]tetradeca-2,4-dienamide, Nsc-650426

Molecular Formula

C₂₈H₄₃N₇O₇

Molecular Weight

589.7 g/mol

InChI Key

LQIPDFIUPOYMPR-AQASXUMVSA-N

1 2D Structure

2D Structure

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(2E,4E)-N-[2-[[2-(1,2-dihydroxyethyl)-4,5-dihydroxy-6-(7H-purin-6-ylamino)oxan-3-yl]amino]-2-oxoethyl]tetradeca-2,4-dienamide

2.1.2 InChI

InChI=1S/C28H43N7O7/c1-2-3-4-5-6-7-8-9-10-11-12-13-19(38)29-14-20(39)34-21-23(40)24(41)28(42-25(21)18(37)15-36)35-27-22-26(31-16-30-22)32-17-33-27/h10-13,16-18,21,23-25,28,36-37,40-41H,2-9,14-15H2,1H3,(H,29,38)(H,34,39)(H2,30,31,32,33,35)/b11-10+,13-12+

2.1.3 InChI Key

LQIPDFIUPOYMPR-AQASXUMVSA-N

2.1.4 Canonical SMILES

CCCCCCCCCC=CC=CC(=O)NCC(=O)NC1C(C(C(OC1C(CO)O)NC2=NC=NC3=C2NC=N3)O)O

2.1.5 Isomeric SMILES

CCCCCCCCC/C=C/C=C/C(=O)NCC(=O)NC1C(C(C(OC1C(CO)O)NC2=NC=NC3=C2NC=N3)O)O

2.2 Synonyms

2.2.1 MeSH Synonyms

1. 6-(4-deoxy-4-((2e,4e)-tetradecadienoylglycyl)amino-l-glycero-b-l-mannoheptopyranosyl)amino-9h-purine

2. Krn 5500

3. Krn-5500

4. Krn5500

2.2.2 Depositor-Supplied Synonyms

1. Spicamycin Analog

2. Nsc650426

3. 151276-95-8

4. Krn5500

5. (2e,4e)-n-[2-[[(2r,3r,4r,5r,6s)-2-[(1s)-1,2-dihydroxyethyl]-4,5-dihydroxy-6-(7h-purin-6-ylamino)oxan-3-yl]amino]-2-oxoethyl]tetradeca-2,4-dienamide

6. Nsc-650426

7. Schembl1650068

8. Chembl1988585

9. (2e,4e)-n-[2-[[(2r,3r,4r,5r,6s)-2-(1,2-dihydroxyethyl)-4,5-dihydroxy-6-(7h-purin-6-ylamino)oxan-3-yl]amino]-2-oxoethyl]tetradeca-2,4-dienamide

10. 4-deoxy-n-(7h-purin-6-yl)-4-(((2,4-tetradecadienoylamino)acetyl)amino)heptopyranosylamine

11. (2e,4e)-n-[2-[[2-(1,2-dihydroxyethyl)-4,5-dihydroxy-6-(7h-purin-6-ylamino)tetrahydropyran-3-yl]amino]-2-oxo-ethyl]tetradeca-2,4-dienamide

12. 6-[4-deoxy-4-(tetradeca-2(e), 4(e)-dienoylglycyl)amino-l-glycero-.beta.-l-manno-hepto-pyranosyl]amino-9h-purine

2.3 Create Date

2005-09-10

3 Chemical and Physical Properties

Molecular Formula	C₂₈H₄₃N₇O₇
Molecular Weight	589.7 g/mol
XLogP3	2.7
Hydrogen Bond Donor Count	8
Hydrogen Bond Acceptor Count	11
Rotatable Bond Count	17
Exact Mass	589.32239674 g/mol
Monoisotopic Mass	589.32239674 g/mol
Topological Polar Surface Area	215 Å²
Heavy Atom Count	42
Formal Charge	0
Complexity	880
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	6
Defined Bond Stereocenter Count	2
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

Protein Synthesis Inhibitors

Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)

POST ENQUIRY